Search NASA⌕ Search

SEARCH · Search NASA

Results for “LABELLING”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 361 records · Page 20

MABAL: a Novel Deep-Learning Architecture for Machine-Assisted Bone Age Labeling

Bone age assessment (BAA) is a commonly performed diagnostic study in pediatric radiology to assess skeletal maturity. The most commonly utilized method for assessment of BAA is the Greulich and Pyle method (Pediatr Radiol 46.9:1269–1274, 2016; Arch Dis Child 81.2:172–173, 1999) atlas. The evaluation of BAA can be a tedious and time-consuming process for the radiologist. As such, several computer-assisted detection/diagnosis (CAD) methods have been proposed for automation of BAA. Classical CAD tools have traditionally relied on hard-coded algorithmic features for BAA which suffer from a variety of drawbacks. Recently, the advent and proliferation of convolutional neural networks (CNNs) has shown promise in a variety of medical imaging applications. There have been at least two published applications of using deep learning for evaluation of bone age (Med Image Anal 36:41–51, 2017; JDI 1–5, 2017). However, current implementations are limited by a combination of both architecture design and relatively small datasets. The purpose of this study is to demonstrate the benefits of a customized neural network algorithm carefully calibrated to the evaluation of bone age utilizing a relatively large institutional dataset. In doing so, this study will aim to show that advanced architectures can be successfully trained from scratch in the medical imaging domain and can generate results that outperform any existing proposed algorithm. The training data consisted of 10,289 images of different skeletal age examinations, 8909 from the hospital Picture Archiving and Communication System at our institution and 1383 from the public Digital Hand Atlas Database. The data was separated into four cohorts, one each for male and female children above the age of 8, and one each for male and female children below the age of 10. The testing set consisted of 20 radiographs of each 1-year-age cohort from 0 to 1 years to 14–15+ years, half male and half female. The testing set included left-hand radiographs done for bone age assessment, trauma evaluation without significant findings, and skeletal surveys. A 14 hidden layer-customized neural network was designed for this study. The network included several state of the art techniques including residual-style connections, inception layers, and spatial transformer layers. Data augmentation was applied to the network inputs to prevent overfitting. A linear regression output was utilized. Mean square error was used as the network loss function and mean absolute error (MAE) was utilized as the primary performance metric. MAE accuracies on the validation and test sets for young females were 0.654 and 0.561 respectively. For older females, validation and test accuracies were 0.662 and 0.497 respectively. For young males, validation and test accuracies were 0.649 and 0.585 respectively. Finally, for older males, validation and test set accuracies were 0.581 and 0.501 respectively. The female cohorts were trained for 900 epochs each and the male cohorts were trained for 600 epochs. An eightfold cross-validation set was employed for hyperparameter tuning. Test error was obtained after training on a full data set with the selected hyperparameters. Using our proposed customized neural network architecture on our large available data, we achieved an aggregate validation and test set mean absolute errors of 0.637 and 0.536 respectively. To date, this is the best published performance on utilizing deep learning for bone age assessment. Our results support our initial hypothesis that customized, purpose-built neural networks provide improved performance over networks derived from pre-trained imaging data sets. We build on that initial work by showing that the addition of state-of-the-art techniques such as residual connections and inception architecture further improves prediction accuracy. This is important because the current assumption for use of residual and/or inception architectures is that a large pre-trained network is required for successful implementation given the relatively small datasets in medical imaging. Instead we show that a small, customized architecture incorporating advanced CNN strategies can indeed be trained from scratch, yielding significant improvements in algorithm accuracy. It should be noted that for all four cohorts, testing error outperformed validation error. One reason for this is that our ground truth for our test set was obtained by averaging two pediatric radiologist reads compared to our training data for which only a single read was used. This suggests that despite relatively noisy training data, the algorithm could successfully model the variation between observers and generate estimates that are close to the expected ground truth.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Synthesis of fluorescent coumarin-labeled organic glass

Polymerization of methyl methacrylate in bulk in the presence of 4-ethynylcoumarin and 4-butadiynylcoumarin (AIBN, 60 °C) leads to the formation of fluorescent polymers. A hypsochromic shift of fluorescence band maxima of polymer solutions is observed in dichloromethane. It was suggested using the quantum chemical calculations that 4-ethynylcoumarin is attached to the macroradical via the terminal carbon atom of the ethynyl group. The samples of fluorescent organic glasses were prepared. It was established that the addition of coumarins do not influence the microhardness of organic glass.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

This phase II clinical trial compared the efficacy and safety of second-line irinotecan and panitumumab treatment (IRI + Pmab) with that of irinotecan, fluoropyrimidines and panitumumab treatment (control) in patients with KRAS wild-type mCRC. The primary endpoint was progression-free survival. In addition, early predictive markers of treatment efficacy were explored. Eighty patients were planned to be recruited. Due to a slow accrual rate, only 48 patients were recruited from 2012 to 2016, of which 23 were allocated to the control group and 25 were allocated to the IRI + Pmab group. The median progression-free survival was 254 days (95% confidence interval, 159–306) for control, and 190 days (95% confidence interval, 159–213) for IRI + Pmab (log-rank test, P = 0.26). The response rate without confirmation was 21.7% (5/23) for control and 40.0% (10/25) for IRI + Pmab. Neutropenia, leukopenia, and anorexia were the most common Grade 3/4 adverse events, and several early drop-outs from the treatment protocol were observed in the control group. As for the biomarkers, carcinoembryonic antigen and lactate dehydrogenase (LDH) smoothly declined immediately after the initial dosing in patients with a partial response or stable disease. After starting treatment, LDH-1 and − 2 increased, while LDH-4 and − 5 decreased, irrespective of tumor response. However, exceptions were frequent. In conclusion, this study failed to prove the safety and efficacy of irinotecan and panitumumab treatment due to insufficient patient accrual. Although LDH and its isozymes changed after initiation of treatment, their ability to predict the tumor response may not surpass that of carcinoembryonic antigen levels. The University Hospital Medical Information Network Clinical Trial Registry: UMIN000007658.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Infections in patients using ventricular-assist devices: Comparison of the diagnostic performance of {sup 18}F-FDG PET/CT scan and leucocyte-labeled scintigraphy

Background: The usage of left-ventricular-assist device (LVAD) is increasing in patients presenting with advanced heart failure. However, device-related infections are a challenge to recognize and to treat, with an important morbidity and mortality rate. The role of nuclear medicine imaging remains not well established for LVAD infections. The present study compared the accuracy of positron emission tomography/computed tomography with {sup 18}F-fludeoxyglucose ({sup 18}F-FDG PET/CT) and radiolabeled leucocyte scintigraphy for the diagnosis of infections in patients supported with a continuous-flow LVAD. Methods: From a prospectively maintained database, we retrospectively analyzed the diagnostic performance of radiolabeled leucocyte scintigraphy and {sup 18}F-FDG PET/CT in 24 patients who had a LVAD with a suspected device-related infection. Both examinations were routinely performed in all patients. Infection was assessed by the International Society for Heart and Lung Transplantation criteria. Results: Twenty-four patients were included: 15 had a specific VAD infection (5 cardiac-LVAD and 10 driveline), 6 had a VAD-related infection, while 3 patients had a non-VAD-related infection. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 95.2%, 66.7%, 95.2%, 66.7%, and 91.6%, respectively, for {sup 18}F-FDG-PET; and 71.4%, 100%, 100%, 33.3%, and 75%, respectively, for leucocyte scintigraphy. {sup 18}F-FDG PET/CT showed significantly higher sensitivity (P = 0.01) than leucocyte scintigraphy. Conclusion: {sup 18}F-FDG PET/CT and radiolabeled leucocyte scintigraphy single-photon emission computed tomography carry high performance in the diagnostic of LVAD infections. {sup 18}F-FDG PET/CT shows significantly higher sensitivity and could be proposed as first-line nuclear medicine procedure. [French] French Abstract: Contexte: L’utilisation du dispositif d’assistance ventriculaire gauche (DAVG) est en utilisation croissante chez les patients avec insuffisance cardiaque avancée. Cependant, les infections liées au dispositif sont un défi à reconnaître et à traiter en raison d’ un taux de morbidité et de mortalité important. Le rôle de l’imagerie de médecine nucléaire n’est pas encore bien établi pour les infections secondaires au DAVG. La présente étude compare la précision de la tomographie par émission de positrons / tomodensitométrie au 18F-fluorodéoxyglucose (18F-FDG TEP/TDM) et la scintigraphie leucocytaire radio-marquée pour le diagnostic d’infections chez des patients porteurs par un DAVG à flux continu. Méthodes: A partir d’une base de données complétée de manière prospective nous avons analysé rétrospectivement les performances diagnostiques de la scintigraphie leucocytaire radio-marquée et de la TEP / TDM au 18F-FDG chez 24 patients ayant un DAVG avec une infection suspectée liée à l’appareillage. Les deux types d’examens scintigraphiques ont été systématiquement réalisé chez tous les patients. Le diagnostic d’infection fut établi selon les critères ISHLT. Résultats: Parmi les 24 patients inclus, 15 avaient une infection spécifique de l’appareillage AVG (5 au niveau de la pompe et/ou canule d’insertion myocardique) et 10 au niveau du driveline, 6 avaient une infection indirectement liée à l’appareillage AVG, tandis que 3 patients avaient une infection non liée au DAVG. La sensibilité, la spécificité, la valeur prédictive positive, la valeur prédictive négative et la précision étaient de 95,2%, 66,7%, 95,2%, 66,7% et 91,6%, respectivement, pour le 18F-FDG-PET et 71,4%, 100%, 100%, 33,3 %, et 75%, respectivement, pour la scintigraphie leucocytaire. La TEP / TDM au 18F-FDG a montré une sensitivité significativement plus élevée (p = 0,01) que la scintigraphie leucocytaire. Conclusion: 18F-FDG TEP/TDM et scintigraphie leucocytaire radio-marquée SPECT s’avèrent très efficaces pour le diagnostic des infections à DVAG. La TEP/TDM au 18F-FDG montre une sensibilité significativement plus élevée et pourrait être proposée en tant que la procédure de médecine nucléaire de premier choix. [Spanish] Spanish Abstract: Antecedentes: El uso de dispositivos de asistencia ventricular izquierda (DAVI) está incrementando en pacientes con insuficiencia cardiaca avanzada. Sin embargo, las infecciones relacionadas al dispositivo representan un reto diagnóstico y de tratamiento, con una importante tasa de morbilidad y mortalidad. El papel de los estudios de imagen de medicina nuclear en las infecciones de DAVI no se ha establecido claramente. El presente estudio comparó la precisión de la tomografía por emisión de positrones/tomografía computada con {sup 18}F-fluorodesoxiglucosa ({sup 18}F-FDG PET/CT) y la gammagrafía con leucocitos marcados para el diagnóstico de infecciones en pacientes utilizando un DAVI de flujo continuo. Métodos: Desde una base de datos obtenida de manera prospectiva, analizamos de manera retrospectiva el rendimiento diagnóstico de la gammagrafía de leucocitos marcados y del {sup 18}F-FDG PET/CT en 24 pacientes quienes tenían un DAVI con sospecha de infección relacionada al dispositivo. Ambos estudios fueron realizados rutinariamente en todos los pacientes. Se determinó la presencia de infección mediante los criterios de la ISHTL. Resultados: Se incluyeron veinticuatro pacientes, de los cuales 15 tuvieron una infección específica de DAV (5 con infecciones DAVI, y 10 con infección del driveline), 6 tuvieron una infección relacionada al DAV, y 3 pacientes tuvieron una infección no relacionada al DAV. La sensibilidad, especificidad, valor predictivo positivo, valor predictivo negativo y precisión diagnóstica fueron 95.2%, 66.7%, 95.2%, 66.7% y 91.6%, respectivamente para {sup 18}F-FDG PET/CT, y 71.4%, 100%, 100%, 33.3% y 75%, respectivamente para la gammagrafía de leucocitos marcados. El {sup 18}F-FDG PET/CT mostró una significativa mayor sensibilidad (p=0.01) que la gammagrafía con leucocitos marcados. Conclusión: El {sup 18}F-FDG PET/CT y la gammagrafía de leucocitos marcados tienen un alto desempeño en el diagnóstico de infecciones de DAVI. El {sup 18}F-FDG PET/CT muestra una significativa mayor sensibilidad y podría ser propuesto como el procedimiento de medicina nuclear de primera línea. [Chinese] Chinese Abstract: 背景: 左心室辅助装置 (LVAD) 越来越多的应用于重度心力衰竭患者。然而, 设备相关的感染有着重要的发病率和死亡率, 并且对其诊断和治疗均是一项挑战。对于 LVAD 相关感染, 核医学影像可扮演的角色一直没有完善。本研究针对装备有连续流式 LVAD 的感染病人,对比了 {sup 18}F-FDG PET/CT 造影术和放射性标记白细胞闪烁扫描法对感染诊断的准确性。 方法: 从一个前瞻性的数据库, 入选了24名疑似设备感染的 LVAD 病人, 并回顾性的分析了放射性标记白细胞闪烁扫描法和 {sup 18}F-FDG PET/CT 的诊断表现。所有病人都常规进行了上述两种检查。利用 ISHLT 标准对感染情况进行评估。 结果: 在入选的 24 名病人中, 15 名有明确的 VAD 感染 (5 名心脏的 LVAD 和 10 名动力传动系统装置), 6 名有 VAD 相关的感染,另外3名有 VAD 无关的感染。对于 {sup 18}F-FDG PET/CT 诊断方法,其敏感性,特异性,阳性预测值,阴性预测值和准确率分别为: 95.2%, 66.7%, 95.2%, 66.7%, 和 91.6%; 而对于白细胞闪烁扫描诊断方法, 其敏感性, 特异性, 阳性预测值,阴性预测值和准确率分别为: 71.4%, 100%, 100%, 33.3% 和 75%。相比于白细胞闪烁扫描, {sup 18}F-FDG PET/CT 明显展现出较高的敏感性 (p=0.01)。 结论: {sup 18}F-FDG PET/CT 和白细胞闪烁扫描 SPECT 对于 LVAD 感染的诊断具有很好的表现。{sup 18}F-FDG PET/CT 展现出较高的敏感性,可以作为核医学的首要检查。.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Development of a novel photoaffinity probe for labeling nocistatin receptor

Highlights: • Biotin-(AC{sub 5}){sub 2}-[Y{sup 6},azF{sup 14}]bNST is a novel nocistatin photoaffinity probe. • Biotin-(AC{sub 5}){sub 2}-[Y{sup 6},azF{sup 14}]bNST inhibits the tactile pain allodynia. • Biotin-(AC{sub 5}){sub 2}-[Y{sup 6},azF{sup 14}]bNST-binding proteins are observed at 58 and 64 kDa. Nocistatin (NST) is a neuropeptide produced from the same precursor protein of opioid peptide nociceptin/orphanin FQ, and it is involved in a broad range of central functions including pain transmission in the nervous system. However, the composition and structure of the receptor(s) for NST remain unclear. Here, we developed NST photoaffinity probe to identify NST receptor. The NST photoaffinity probe contains an azide moiety for the tagging of the binding protein as well as biotin for protein detection. Intrathecal administration of a NST photoaffinity probe, biotin-(AC{sub 5}){sub 2}-[Y{sup 6},azF{sup 14}]bNST, inhibited the nociceptin/orphanin FQ-evoked tactile pain allodynia in a manner similar to that of NST. The biotin-(AC{sub 5}){sub 2}-[Y{sup 6},azF{sup 14}]bNST-binding proteins were primarily localized in the gray matter of the spinal cord. After photo-crosslinking of the protein complex with biotin-(AC{sub 5}){sub 2}-[Y{sup 6},azF{sup 14}]bNST, two dominant binding protein bands were observed at 58 and 64 kDa. Thus, biotin-(AC{sub 5}){sub 2}-[Y{sup 6},azF{sup 14}]bNST has pharmacological activity and is useful for characterizing the NST receptor.

60 APPLIED LIFE SCIENCES↗

Selective bio-labeling and induced apoptosis of hematopoietic cancer cells using dual-functional polyethylenimine-caged platinum nanoclusters

Highlights: • Possess dual-functionality: fluorescence and anti-cancer property applied as biomarkers and anti-cancer drugs simultaneously. • First employed in biological imaging of hematopoietic suspension cells for Pt NCs. • More inclined enter blood cancer cells K562 and BV173 than normal PBMCs. • Selective induction of apoptosis in hematopoietic cancer cells K562 and BV173. In the past decades, platinum (Pt) is employed to clinical treatment of various cancers. However, for Pt-based drugs, especially Pt in +2 state [Pt (II)], such as cisplatin, number of drawbacks impede their anticancer efficiency including poor pharmacology, fast blood clearance, systemic toxicities causing from poor specificity and excretion of drug through kidneys. Herein, we developed dual-functional ultrafine polyethylenimine caged platinum nanoclusters (PEI-caged Pt NCs), which were utilized in biological imaging of the suspension cells system as fluorescent markers, and selective inhibition of hematopoietic malignancies as anticancer chemotherapeutics simultaneously. These zerovalent Pt NCs are capable to selectively enter into blood cancer cells (K562, BV173 cell lines) when compared to the peripheral blood mononucleated cells (PBMCs) from healthy donors, in addition, it can specifically induce pro-apoptotic protein expression (p53, PUMA, cleaved caspase) in hematopoietic cancer cells and promote cell apoptosis. Avoiding the adding of other fluorescent bio-markers, these Pt NCs showed great potential in diagnosis and treatment of hematopoietic system disease, such as acute myeloid leukemia, lymphoma, myeloma, etc.

60 APPLIED LIFE SCIENCES↗